Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diagnosis and Treatment of Patients With Inborn Errors of Metabolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00369421
Recruitment Status : Recruiting
First Posted : August 29, 2006
Last Update Posted : November 23, 2020
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )

Brief Summary:

Researchers intend on diagnosing and treating certain inborn errors of metabolism. By doing this researchers hope to expand their knowledge about these disorders and provide access to patients of interest for research, teaching, and clinical experience.

Patients participating in this study will be examined and treated on an out patient basis, if practical. However, patients requiring specialized tests or treatments will be admitted to the NIH Clinical Center as necessary. Researchers will use only accepted medical procedures in diagnosing (medical history, physical examinations, X-ray studies, eye examinations, blood tests, and urine tests) and treating the patients involved in this study. Additional tests may be required on a case to case basis.

Many patients seen in this study will go on to be enrolled in a specific disease-related research study.<TAB>


Condition or disease
Arterial Calcification Due to CD73-Deficiency (ACDC)

Detailed Description:

We propose to characterize the etiology and natural history of rare inborn errors of metabolism and other genetic disorders, both known and yet-to-be discovered. In so doing, we will expand our knowledge about these disorders and provide access to patients of interest for research, teaching, and clinical experience. Individual patients seen under this protocol have prompted the establishment of specific disease-related protocols involving intensive natural history studies and innovative therapies. In the past, this protocol provided an avenue for admitting patients as part of the NIH Undiagnosed Diseases Program (UDP). Currently, this protocol continues its

longstanding role in investigating individuals who are of interest to the Section on

Human Biochemical Genetics or to the protocol s Associate Investigators.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 4000 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Diagnosis and Treatment of Patients With Inborn Errors of Metabolism or Other Genetic Disorders
Actual Study Start Date : September 12, 1978


Group/Cohort
Unique Disorders
Unique Disorders



Primary Outcome Measures :
  1. Clinical phenotyping [ Time Frame: years to decades followup ]
    Clinical characterization


Secondary Outcome Measures :
  1. Molecular genotyping [ Time Frame: Years to decades ]
    Molecular genotyping.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Unique Disorders
Criteria
  • Inclusion/Exclusion criteria

Patients enrolled in this protocol will have been referred with a known or suspected inborn error of metabolism, heritable disorder, or genetic predisposition. Examples include inherited developmental defects or diatheses toward infections, cancer, or an environmentally induced disease. The principal investigator, along with consulting specialists, will review the medical records of prospective subjects and offer admission based upon the potential to help the individual, to learn from the patient, or to initiate clinical or basic research suggested by the patient s workup. This protocol is not intended to serve as an umbrella protocol for small studies of specific disorders. In general, no more than 5 families known to have the same disorder will be investigated under this protocol.

Some subjects will be relatives of patients with known diagnoses, and their specimens will be obtained for the purpose of heterozygote testing or to serve as controls to help diagnose the proband. All subjects shall be admitted as inpatients or outpatients at the discretion of the principal investigator, based upon particular research interests and expertise.

We will not admit patients under one month of age to this protocol. This exclusion occurs because there is no urgency for a very early diagnosis and care is more readily proffered to older individuals at the Clinical Center. Patients under two years of age will be admitted only if they are medically stable and require admission to the Clinical Center for diagnosis.

Normal adult volunteers will be enrolled to provide control blood and urine specimens. NIH employees and members of their immediate families may participate in this protocol as normal volunteers. We will follow the Guidelines for the Inclusion of Employees in NIH Research Studies and will give each employee a copy of the NIH information sheet on Employee Research Participation.

For NIH employees:

  1. Neither participation nor refusal to participate will have an effect, either beneficial or adverse, on the participant s employment or work situation.
  2. The NIH information sheet regarding NIH employee research participation will be distributed to all potential subjects who are NIH employees.
  3. The employee subject s privacy and confidentiality will be preserved in accordance with NIH Clinical Center policies, which define the scope and limitations of the protections.
  4. For NIH employee subjects, consent will be obtained by an individual independent of the employee s team. Those in a supervisory position to any -12- employee and co-workers of the employee will not obtain consent.
  5. The importance of maintaining confidentiality when obtaining potentially sensitive and private information from co-workers or subordinates will bereviewed with the study staff at least annually and more often if warranted.

Vulnerable subjects (e.g., children and adults unable to provide consent) are included because their investigation under this protocol can lead to diagnosis, prognosis, therapy, and membership in a community devoted to improving their lives.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00369421


Contacts
Layout table for location contacts
Contact: William A Gahl, M.D. (301) 402-2739 gahlw@mail.nih.gov

Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov   
Sponsors and Collaborators
National Human Genome Research Institute (NHGRI)
Investigators
Layout table for investigator information
Principal Investigator: William A Gahl, M.D. National Human Genome Research Institute (NHGRI)
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: National Human Genome Research Institute (NHGRI)
ClinicalTrials.gov Identifier: NCT00369421    
Other Study ID Numbers: 760238
76-HG-0238
First Posted: August 29, 2006    Key Record Dates
Last Update Posted: November 23, 2020
Last Verified: November 18, 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) ):
Biochemical Diseases
Rare Diseases
Family Studies
Screening
Next Generation Sequencing
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolism, Inborn Errors
Metabolic Diseases
Genetic Diseases, Inborn